Search tips
Search criteria 


Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
Antimicrob Agents Chemother. 1991 December; 35(12): 2591–2595.
PMCID: PMC245436

Long-term protection of polyaspartic acid in experimental gentamicin nephrotoxicity.


Polyaspartic Acid (PAA) protects the kidney from experimental gentamicin nephrotoxicity despite large increases in renal cortical gentamicin content. In these experiments, prominent cytoplasmic vacuoles were noted in all animals that received PAA with or without gentamicin. The present study showed that there were no renal structural or functional consequences of PAA given alone or with gentamicin for up to 14 days, followed by a 16-week washout period. Creatinine clearance was similar to that of controls in animals that received gentamicin and in those that received PAA alone. Thus, complete functional protection was conferred by PAA and gentamicin, confirming previous reports from our laboratory. There was no protection by PAA from the nephrotoxic effects of mercuric chloride and cis-platinum.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (785K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Beauchamp D, Laurent G, Maldague P, Abid S, Kishore BK, Tulkens PM. Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid. J Pharmacol Exp Ther. 1990 Nov;255(2):858–866. [PubMed]
  • Beauchamp D, Laurent G, Maldague P, Tulkens PM. Reduction of gentamicin nephrotoxicity by the concomitant administration of poly-l-aspartic acid and poly-l-asparagine in rats. Arch Toxicol Suppl. 1986;9:306–309. [PubMed]
  • English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation. 1987 Jul;44(1):135–141. [PubMed]
  • Gilbert DN, Wood CA, Kohlhepp SJ, Kohnen PW, Houghton DC, Finkbeiner HC, Lindsley J, Bennett WM. Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J Infect Dis. 1989 May;159(5):945–953. [PubMed]
  • Kishore BK, Kállay Z, Lambricht P, Laurent G, Tulkens PM. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. I. Polyaspartic acid binds gentamicin and displaces it from negatively charged phospholipid layers in vitro. J Pharmacol Exp Ther. 1990 Nov;255(2):867–874. [PubMed]
  • Matzke GR, Lucarotti RL, Shapiro HS. Controlled comparison of gentamicin and tobramycin nephrotoxicity. Am J Nephrol. 1983 Jan-Feb;3(1):11–17. [PubMed]
  • MAUNSBACH AB, MADDEN SC, LATTA H. Light and electron microscopic changes in proximal tubules of rats after administration of glucose, mannitol, sucrose, or dextran. Lab Invest. 1962 Jun;11:421–432. [PubMed]
  • Ramsammy LS, Josepovitz C, Lane BP, Kaloyanides GJ. Polyaspartic acid protects against gentamicin nephrotoxicity in the rat. J Pharmacol Exp Ther. 1989 Jul;250(1):149–153. [PubMed]
  • Williams PD, Hottendorf GH. Inhibition of renal membrane binding and nephrotoxicity of gentamicin by polyasparagine and polyaspartic acid in the rat. Res Commun Chem Pathol Pharmacol. 1985 Feb;47(2):317–320. [PubMed]
  • Williams PD, Hottendorf GH, Bennett DB. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides. J Pharmacol Exp Ther. 1986 Jun;237(3):919–925. [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)